Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L21	wo009924462.pn.	0	L21
L20	9924462.pn.	2	L20
L19	9924075.pn.	3	L19
L18	l7 and L17	7	L18
L17	l1 same l2 same l3	9	L17
L16	l1 same l13	2	L16
L15	l5 and l6 and L14	1	L15
L14	l1 and L13	101	L14
L13	serum albumin	31773	L13
L12	l1 and l7	132	L12
L11	l1 same l7	3	L11
L10	L9 and l5 and l6 and l7	44	L10
L9	l2 same (l3 and l4)	2867	L9
L8	l1 and l2 and l3 and l4 and l5 and l6 and l7	1	L8
L7	albumin	51789	L7
L6	maleimido	2405	L6
L5	succinimidyl	4070	L5
L4	amino near (terminus or terminal)	25607	L4
L3	carboxy near (terminus or terminal)	9948	L3
L2	peptide	104057	L2
L1	therapeutic peptide	390	L1

END OF SEARCH HISTORY

```
Welcome to STN International!  Enter x:x

LOGINID:ssspta1619lxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Jan 25  BLAST(R) searching in REGISTRY available in STN on the Web
 NEWS  3  Jan 25  Searching with the P indicator for Preparations
 NEWS  4  Jan 29  FSTA has been reloaded and moves to weekly updates
 NEWS  5  Feb 01  DKILIT now produced by FIZ Karlsruhe and has a new update
                  frequency
 NEWS  6  Feb 19  Access via Tymnet and SprintNet Eliminated Effective 3/31/02
 NEWS  7  Mar 08  Gene Names now available in BIOSIS
 NEWS  8  Mar 22  TOXLIT no longer available
 NEWS  9  Mar 22  TRCTHERMO no longer available
 NEWS 10  Mar 28  US Provisional Priorities searched with P in CA/CAplus
                  and USPATFULL
 NEWS 11  Mar 28  LIPINSKI/CALC added for property searching in REGISTRY

 NEWS EXPRESS  February 1 CURRENT WINDOWS VERSION IS V6.0d,
               CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 15:13:47 ON 29 MAR 2002

=> fil caplus uspatfull biosis embase
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21

FILE 'CAPLUS' ENTERED AT 15:14:12 ON 29 MAR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE 'USPATFULL' ENTERED AT 15:14:12 ON 29 MAR 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:14:12 ON 29 MAR 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 15:14:12 ON 29 MAR 2002
COPYRIGHT (C) 2002 Elsevier Science B.V.  All rights reserved.

=> e bridon dominique/au
E1            6     BRIDON D P/AU
E2            2     BRIDON DA GRACA SGARBI DIANA/AU
E3           17 --> BRIDON DOMINIQUE/AU
E4           38     BRIDON DOMINIQUE P/AU
E5            2     BRIDON F/AU
E6            2     BRIDON HELENE/AU
E7           34     BRIDON J M/AU
E8            1     BRIDON J N/AU
E9           21     BRIDON JEAN MICHEL/AU
E10           3     BRIDON JEAN NOEL/AU
E11           1     BRIDON L/AU
E12           2     BRIDON LAURENCE/AU

=> s e3 or e4 or e1
L1           61 "BRIDON DOMINIQUE"/AU OR "BRIDON DOMINIQUE P"/AU OR "BRIDON D
               P"/AU

=> e exrin alan/cn
   REG1stRY INITIATED
Substance data EXPAND from CAS REGISTRY in progress...


E1            1     EXPROTECT/CN
E2            1     EXRIN/CN
E3            0 --> EXRIN ALAN/CN
E4            1     EXS 07/CN
E5            1     EXSB (RICKETTSIA CONORI STRAIN MALISH 7 GENE EXSB)/CN
E6            1     EXSB PROTEIN (CAULOBACTER CRESCENTUS GENE CC3160)/CN
E7            1     EXSB PROTEIN (VIBRIO CHOLERAE STRAIN N16961 GENE VC1366)/CN
E8            1     EXSEROHILONE/CN
E9            1     EXSERTIFOLIN A/CN
E10           1     EXSERTIFOLIN B/CN
E11           1     EXSERTIFOLIN C/CN
E12           1     EXSERTIFOLIN D/CN


=> e ezrin alan/cn
   REG1stRY INITIATED
Substance data EXPAND from CAS REGISTRY in progress...


E1            1     EZRIN (OX CLONE 2-8 REDUCED)/CN
E2            1     EZRIN (RAT CLONE DRIC32 C-TERMINAL FRAGMENT)/CN
E3            0 --> EZRIN ALAN/CN
E4            1     EZRIN, PRO- (HUMAN)/CN
E5            1     EZRIN-MOESIN-LIKE PROTEIN (DROSOPHILA MELANOGASTER CLONE
D17
```

```
                    C-TERMINAL FRAGMENT)/CN
E6          1       EZRIN-RADIXIN-MOESIN BINDING PHOSPHOPROTEIN-50 (HUMAN
PLACEN
                    TA)/CN
E7          1       EZT-MZC/CN
E8          1       EZTLITE/CN
E9          1       EZTLITE (FE3PB(TE2O10).XH2O)/CN
E10         1       EZTSK/CN
E11         1       EZTSK 38/CN
E12         1       EZTSN/CN


=> e milner peter/cn
   REGIstRY INITIATED
Substance data EXPAND from CAS REGISTRY in progress...



E1          1       MILNACIPRAN HYDROCHLORIDE/CN
E2          1       MILNEB/CN
E3          0 --> MILNER PETER/CN
E4          1       MILODISTIM/CN
E5          1       MILOGARD/CN
E6          1       MILOLIDE A/CN
E7          1       MILOLIDE B/CN
E8          1       MILOLIDE C/CN
E9          1       MILOLIDE D/CN
E10         1       MILOLIDE E/CN
E11         1       MILOLIDE F/CN
E12         1       MILON/CN


=> e holmes darren/au
E1          2       HOLMES DANIEL J/AU
E2          1       HOLMES DANIEL SCOTT/AU
E3          0 --> HOLMES DARREN/AU
E4         21       HOLMES DARREN L/AU
E5          1       HOLMES DARREN LEE/AU
E6         25       HOLMES DAVID/AU
E7          5       HOLMES DAVID A/AU
E8          6       HOLMES DAVID ALAN/AU
E9          1       HOLMES DAVID B/AU
E10         4       HOLMES DAVID C/AU
E11         1       HOLMES DAVID E/AU
E12        32       HOLMES DAVID F/AU

=> s e4 or e5
           21 "HOLMES DARREN L"/AU
            1 "HOLMES DARREN LEE"/AU
L2         22 "HOLMES DARREN L"/AU OR "HOLMES DARREN LEE"/AU

=> e thibaudeau karen/cn
   REGIstRY INITIATED
Substance data EXPAND from CAS REGISTRY in progress...



E1          1       THIAZYL TRIFLUORIDE (NSF3)/CN
E2          1       THIAZYLDIFLUORIDE DIMETHYLAMIDE/CN
E3          0 --> THIBAUDEAU KAREN/CN
```

```
E4            1      THIBENDOLE/CN
E5            1      THIBENZAZOLINE/CN
E6            1      THIBENZOL/CN
E7            1      THIBENZOLE/CN
E8            1      THIBENZOLE 200/CN
E9            1      THIBETINE/CN
E10           1      THIBETOLIDE/CN
E11           1      THIBON/CN
E12           1      THIBONE/CN


=> e ezrin alan/au
E1            1      EZRIN A/AU
E2            6      EZRIN A M/AU
E3            4  --> EZRIN ALAN/AU
E4           31      EZRIN ALAN M/AU
E5            2      EZRIN ALAN MARK/AU
E6            1      EZRIN AM/AU
E7            7      EZRIN C/AU
E8           41      EZRIN CALVIN/AU
E9           15      EZRIN M/AU
E10          24      EZRIN MYER/AU
E11           1      EZRIN WATERS C/AU
E12           3      EZRIN WATERS CHERYL/AU

=> s e3 or e4 or e5 or e6 or e2 or e1
              4 "EZRIN ALAN"/AU
             31 "EZRIN ALAN M"/AU
              2 "EZRIN ALAN MARK"/AU
              1 "EZRIN AM"/AU
              6 "EZRIN A M"/AU
              1 "EZRIN A"/AU
L3           45 "EZRIN ALAN"/AU OR "EZRIN ALAN M"/AU OR "EZRIN ALAN MARK"/AU
OR
                 "EZRIN AM"/AU OR "EZRIN A M"/AU OR "EZRIN A"/AU

=> e thibaudeau karen/au
E1            1      THIBAUDEAU JEAN PIERRE/AU
E2            1      THIBAUDEAU K/AU
E3            5  --> THIBAUDEAU KAREN/AU
E4            7      THIBAUDEAU L/AU
E5            1      THIBAUDEAU LAURENT/AU
E6            1      THIBAUDEAU P/AU
E7            1      THIBAUDEAU PASCAL/AU
E8            1      THIBAUDEAU RENE/AU
E9            1      THIBAUDEAU S A/AU
E10           3      THIBAUDET GENEVIEVE/AU
E11           3      THIBAUDET M A/AU
E12           1      THIBAUDET MARIE A/AU

=> s e3 or e2
              5 "THIBAUDEAU KAREN"/AU
              1 "THIBAUDEAU K"/AU
L4            6 "THIBAUDEAU KAREN"/AU OR "THIBAUDEAU K"/AU

=> d his

     (FILE 'HOME' ENTERED AT 15:13:47 ON 29 MAR 2002)

     FILE 'CAPLUS, USPATFULL, BIOSIS, EMBASE' ENTERED AT 15:14:12 ON 29 MAR
```

```
     2002
                E BRIDON DOMINIQUE/AU
L1           61 S E3 OR E4 OR E1

     FILE 'REGISTRY' ENTERED AT 15:15:01 ON 29 MAR 2002
                E EXRIN ALAN/CN

     FILE 'CAPLUS' ENTERED AT 15:15:01 ON 29 MAR 2002

     FILE 'REGISTRY' ENTERED AT 15:15:10 ON 29 MAR 2002
                E EZRIN ALAN/CN

     FILE 'CAPLUS' ENTERED AT 15:15:10 ON 29 MAR 2002

     FILE 'REGISTRY' ENTERED AT 15:15:26 ON 29 MAR 2002
                E MILNER PETER/CN

     FILE 'CAPLUS' ENTERED AT 15:15:27 ON 29 MAR 2002
                E HOLMES DARREN/AU
L2           22 S E4 OR E5

     FILE 'REGISTRY' ENTERED AT 15:16:09 ON 29 MAR 2002
                E THIBAUDEAU KAREN/CN

     FILE 'CAPLUS' ENTERED AT 15:16:09 ON 29 MAR 2002
                E EZRIN ALAN/AU
L3           45 S E3 OR E4 OR E5 OR E6 OR E2 OR E1
                E THIBAUDEAU KAREN/AU
L4            6 S E3 OR E2

=> e milner peter/au
E1            9     MILNER PAUL F/AU
E2            1     MILNER PAULA/AU
E3            7 --> MILNER PETER/AU
E4           25     MILNER PETER G/AU
E5            2     MILNER PETER GERARD/AU
E6           20     MILNER PETER H/AU
E7           13     MILNER PETER HENRY/AU
E8            2     MILNER PETER M/AU
E9            5     MILNER PETER W/AU
E10           1     MILNER Q/AU
E11           1     MILNER Q J W/AU
E12          31     MILNER R/AU

=> s e3 or e4 or e5
             7 "MILNER PETER"/AU
            25 "MILNER PETER G"/AU
             2 "MILNER PETER GERARD"/AU
L5          34 "MILNER PETER"/AU OR "MILNER PETER G"/AU OR "MILNER PETER
GERARD
               "/AU

=> d his

     (FILE 'HOME' ENTERED AT 15:13:47 ON 29 MAR 2002)

     FILE 'CAPLUS, USPATFULL, BIOSIS, EMBASE' ENTERED AT 15:14:12 ON 29 MAR
     2002
                E BRIDON DOMINIQUE/AU
L1           61 S E3 OR E4 OR E1
```

```
     FILE 'REGISTRY' ENTERED AT 15:15:01 ON 29 MAR 2002
               E EXRIN ALAN/CN

     FILE 'CAPLUS' ENTERED AT 15:15:01 ON 29 MAR 2002

     FILE 'REGISTRY' ENTERED AT 15:15:10 ON 29 MAR 2002
               E EZRIN ALAN/CN

     FILE 'CAPLUS' ENTERED AT 15:15:10 ON 29 MAR 2002

     FILE 'REGISTRY' ENTERED AT 15:15:26 ON 29 MAR 2002
               E MILNER PETER/CN

     FILE 'CAPLUS' ENTERED AT 15:15:27 ON 29 MAR 2002
               E HOLMES DARREN/AU
L2            22 S E4 OR E5

     FILE 'REGISTRY' ENTERED AT 15:16:09 ON 29 MAR 2002
               E THIBAUDEAU KAREN/CN

     FILE 'CAPLUS' ENTERED AT 15:16:09 ON 29 MAR 2002
               E EZRIN ALAN/AU
L3            45 S E3 OR E4 OR E5 OR E6 OR E2 OR E1
               E THIBAUDEAU KAREN/AU
L4             6 S E3 OR E2
               E MILNER PETER/AU
L5            34 S E3 OR E4 OR E5

=> s l1 or l2 or l3 or l4 or l5
L6           117 L1 OR L2 OR L3 OR L4 OR L5

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7           117 DUP REM L6 (0 DUPLICATES REMOVED)

=> s l7 py>2000
MISSING OPERATOR L7 PY>2000
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l7 and py>2000
L8           117 S L7
         1159102 PY>2000
L9            21 L8 AND PY>2000

=> l9 and therapeutic peptide
L9 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l9 and therapeutic peptide
          122288 THERAPEUTIC
          270090 PEPTIDE
              79 THERAPEUTIC PEPTIDE
                   (THERAPEUTIC(W)PEPTIDE)
L10            1 L9 AND THERAPEUTIC PEPTIDE

=> d ibib abs
```

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:824291 CAPLUS
DOCUMENT NUMBER: 134:21425
TITLE: Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
INVENTOR(S): **Bridon, Dominique P.; Ezrin, Alan M. ; Milner, Peter G.; Holmes, Darren L.; Thibaudeau, Karen**
PATENT ASSIGNEE(S): Conjuchem, Inc., Can.
SOURCE: PCT Int. Appl., 733 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069900	A2	20001123	WO 2000-US13576	20000517 <--
WO 2000069900	A3	20010215		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2000070665	A2	20001123	WO 2000-IB763	20000517 <--
WO 2000070665	A3	20010419		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1105409	A2	20010613	EP 2000-936023	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1171582	A2	20020116	EP 2000-929748	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.:

US 1999-134406P	P	19990517
US 1999-153406P	P	19990910
US 1999-159783P	P	19991015
WO 2000-IB763	W	20000517
WO 2000-US13576	W	20000517

AB A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the

N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. The solid phase peptide synthesis of a no. of derivs. with 3-maleimidopropionic acid (3-MPA) is described. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity. Thus, the percentage of a K5 kringle peptide (Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH2) conjugated to human serum albumin via MPA remained relatively const. through a 24-h plasma assay in contrast to unmodified K5 which decreased to 9% of the original amt. of K5 in only 4 h in plasma.

```
=> s l7 and py<2000
L11          117 S L7
      19715220 PY<2000
L12          103 L11 AND PY<2000

=> s l12 and therapeutic peptide
          122288 THERAPEUTIC
          270090 PEPTIDE
              79 THERAPEUTIC PEPTIDE
                 (THERAPEUTIC(W)PEPTIDE)
L13            0 L12 AND THERAPEUTIC PEPTIDE

=> s l12 and peptide
          270090 PEPTIDE
L14           17 L12 AND PEPTIDE

=> s l14 and albumin
          110074 ALBUMIN
L15            1 L14 AND ALBUMIN

=> d ibib abs

L15  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:         1999:325826  CAPLUS
DOCUMENT NUMBER:          130:349387
TITLE:                    Affinity markers for human serum albumin
INVENTOR(S):              Krantz, Alexander; Huang, Wolin; Hanel, Arthur M.;
                          Holmes, Darren L.; Bridon, Dominique
                          P.
PATENT ASSIGNEE(S):       Conjuchem, Inc., Can.
SOURCE:                   PCT Int. Appl., 79 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   4
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 9924075         A2   19990520       WO 1998-US23705  19981106 <--
     WO 9924075         A3   19990902
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
```

```
            KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
            NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
            UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
            FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
            CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    CA 2305597        AA   19990520       CA 1998-2305597  19981106 <--
    AU 9915196        A1   19990531       AU 1999-15196    19981106 <--
    EP 1056474        A2   20001206       EP 1998-959387   19981106
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    EP 1167383        A1   20020102       EP 2001-121557   19981106
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.:                  US 1997-64705P   P  19971107
                                        US 1998-77927P   P  19980313
                                        EP 1998-956656   A3 19981106
                                        WO 1998-US23705  W  19981106
OTHER SOURCE(S):         MARPAT 130:349387
AB   Methods and compns. are provided for identifying compds. having affinity
     or complementarity to a target mol.  Compds. according to the invention
     may be described by the formula E-Ca-R-Cb-A, wherein E is a therapeutic
or
     diagnostic agent, R is a reactive group, Ca and Cb are connector groups
     between E and R and between R and A, resp., and A is a group having an
     affinity for human serum albumin, wherein affinity group A
     comprises a sequence of amino acid residues -O1-O2-X1-X2-B in which the
     amino acid residues are independently selected from the group of all
     twenty naturally occurring amino acids.  Compds. according to the
     invention may be used for labeling the target mol., particularly where
the
     target mol. is naturally found in a complex mixt., such as a physiol.
     fluid, like blood.  By affinity labeling in vivo, the lifetime of
physiol.
     active entities can be greatly enhanced by becoming bound to long-lived
     blood components.  The covalently bound entity may also serve as an
     antagonist or agonist of a particular binding protein or as an enzyme
     inhibitor.  One compd. prepd. was biotin-Gly-OPh-CO-FIYEE-NH2 (Ph =
     p-C6H4).


=> d his

     (FILE 'HOME' ENTERED AT 15:13:47 ON 29 MAR 2002)

     FILE 'CAPLUS, USPATFULL, BIOSIS, EMBASE' ENTERED AT 15:14:12 ON 29 MAR
     2002
               E BRIDON DOMINIQUE/AU
L1           61 S E3 OR E4 OR E1

     FILE 'REGISTRY' ENTERED AT 15:15:01 ON 29 MAR 2002
               E EXRIN ALAN/CN

     FILE 'CAPLUS' ENTERED AT 15:15:01 ON 29 MAR 2002

     FILE 'REGISTRY' ENTERED AT 15:15:10 ON 29 MAR 2002
               E EZRIN ALAN/CN

     FILE 'CAPLUS' ENTERED AT 15:15:10 ON 29 MAR 2002
```

```
     FILE 'REGISTRY' ENTERED AT 15:15:26 ON 29 MAR 2002
               E MILNER PETER/CN

     FILE 'CAPLUS' ENTERED AT 15:15:27 ON 29 MAR 2002
               E HOLMES DARREN/AU
L2           22 S E4 OR E5

     FILE 'REGISTRY' ENTERED AT 15:16:09 ON 29 MAR 2002
               E THIBAUDEAU KAREN/CN

     FILE 'CAPLUS' ENTERED AT 15:16:09 ON 29 MAR 2002
               E EZRIN ALAN/AU
L3           45 S E3 OR E4 OR E5 OR E6 OR E2 OR E1
               E THIBAUDEAU KAREN/AU
L4            6 S E3 OR E2
               E MILNER PETER/AU
L5           34 S E3 OR E4 OR E5
L6          117 S L1 OR L2 OR L3 OR L4 OR L5
L7          117 DUP REM L6 (0 DUPLICATES REMOVED)
L8          117 S L7
L9           21 S L7 AND PY>2000
L10           1 S L9 AND THERAPEUTIC PEPTIDE
L11         117 S L7
L12         103 S L7 AND PY<2000
L13           0 S L12 AND THERAPEUTIC PEPTIDE
L14          17 S L12 AND PEPTIDE
L15           1 S L14 AND ALBUMIN

=> d l14 ibib abs

L14  ANSWER 1 OF 17  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:         1999:325963  CAPLUS
DOCUMENT NUMBER:          130:325398
TITLE:                    Novel conjugates of RGD-containing peptides and
                          endogenous carriers
INVENTOR(S):              Bridon, Dominique P.; Ezrin, Alan M.
                          ; Holmes, Darren L.; Krantz, Alexander;
                          Thibaudeau, Karen; Blanchard, Dominique
PATENT ASSIGNEE(S):       Conjuchem, Inc., Can.
SOURCE:                   PCT Int. Appl., 36 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   4
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 9924462         A2   19990520       WO 1998-US23702  19981106 <--
     WO 9924462         A3   19990826
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
             NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
             UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 9913856         A1   19990531       AU 1999-13856    19981106 <--
     EP 1028971         A2   20000823       EP 1998-957648   19981106
```

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2001522863 T2 20011120 JP 2000-520470 19981106

EP 1167383 A1 20020102 EP 2001-121557 19981106

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: US 1997-64705P P 19971107
EP 1998-956656 A3 19981106
WO 1998-US23702 W 19981106

AB Conjugates are prepd. from RGD contg. peptides, by combining said peptides or analog with a material providing a functionally reactive group capable of reacting with a blood component (preferably a mobile blood cell or endogenous protein). The conjugates may be administered to patients to provide anti-platelet or anti-adhesion properties through the inhibition of the binding of fibrinogen to the GPIIb/IIIa receptor, and may also be used as probes for receptor activity. The administration to the patient may be made either in vivo or ex vivo and may be performed by either introducing the RGD contg. **peptide** including the reactive functional group into the patient's vascular system or prepg. such a conjugate externally and introducing that conjugate to the patient's vascular system. Thus, **peptide** Ac-RIARGDFPDDRK-NH2 was synthesized using solid-phase methods, and isolated as the tetra-trifluoroacetic acid salt or further derivatized with N-(.gamma.-maleimidobutyryloxy)succinimide or ethylene glycol-bis(succinimidyl-succinate), to give three **peptide** salts, which were then conjugated to human plasma proteins. In in vivo tests, the three RGD-contg. **peptide** prepns. showed, for example, IC50 values of 5.7-27.61 .mu.M in platelet-poor plasma aggregation tests.

=> d 2 ibib abs
1 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):end

=> d l14 2 ibib abs

L14 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:325826 CAPLUS
DOCUMENT NUMBER: 130:349387
TITLE: Affinity markers for human serum albumin
INVENTOR(S): Krantz, Alexander; Huang, Wolin; Hanel, Arthur M.; **Holmes, Darren L.; Bridon, Dominique P.**
PATENT ASSIGNEE(S): Conjuchem, Inc., Can.
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924075	A2	19990520	WO 1998-US23705	19981106 <--
WO 9924075	A3	19990902		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,

KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2305597	AA	19990520	CA 1998-2305597	19981106 <--
AU 9915196	A1	19990531	AU 1999-15196	19981106 <--
EP 1056474	A2	20001206	EP 1998-959387	19981106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1167383	A1	20020102	EP 2001-121557	19981106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.:
US 1997-64705P P 19971107
US 1998-77927P P 19980313
EP 1998-956656 A3 19981106
WO 1998-US23705 W 19981106

OTHER SOURCE(S): MARPAT 130:349387

AB Methods and compns. are provided for identifying compds. having affinity or complementarity to a target mol. Compds. according to the invention may be described by the formula E-Ca-R-Cb-A, wherein E is a therapeutic or diagnostic agent, R is a reactive group, Ca and Cb are connector groups between E and R and between R and A, resp., and A is a group having an affinity for human serum albumin, wherein affinity group A comprises a sequence of amino acid residues -O1-O2-X1-X2-B in which the amino acid residues are independently selected from the group of all twenty naturally occurring amino acids. Compds. according to the invention may be used for labeling the target mol., particularly where the target mol. is naturally found in a complex mixt., such as a physiol. fluid, like blood. By affinity labeling in vivo, the lifetime of physiol. active entities can be greatly enhanced by becoming bound to long-lived blood components. The covalently bound entity may also serve as an antagonist or agonist of a particular binding protein or as an enzyme inhibitor. One compd. prepd. was biotin-Gly-OPh-CO-FIYEE-NH2 (Ph = p-C6H4).

=> d l14 3 ibib abs

L14 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:785565 CAPLUS
DOCUMENT NUMBER: 130:35363
TITLE: Hepatitis GB virus synthetic peptides and uses thereof
INVENTOR(S): Dawson, George J.; Pilot-Matias, Tami J.; **Bridon, Dominique P.**; Schroeder-Poliak, Pamella A.; Knigge, Mark F.; Jaffe, Keeve D.; Mushahwar, Isa K.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S., 28 pp., Cont.-in-part of U.S. Ser. No. 417,629.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 5843450	A	19981201	US 1995-473475	19950607 <--
CA 2166313	AA	19950817	CA 1995-2166313	19950214 <--
JP 10337193	A2	19981222	JP 1998-111629	19950214 <--
US 5981172	A	19991109	US 1995-417629	19950406 <--
CA 2178538	AA	19961208	CA 1996-2178538	19960607 <--
EP 747394	A2	19961211	EP 1996-109205	19960607 <--
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
JP 09040694	A2	19970210	JP 1996-146106	19960607 <--

PRIORITY APPLN. INFO.:

US 1994-196030	B2	19940214
US 1994-242654	B2	19940513
US 1994-283314	B2	19940729
US 1994-344184	B2	19941123
US 1994-344190	B2	19941123
US 1995-377557	B2	19950130
US 1995-417629	A2	19950406
US 1995-424550	A2	19950605
US 1994-344185	A	19941123
US 1995-344557	A	19950127
JP 1995-521441	A3	19950214
WO 1995-US2118	A2	19950214
US 1995-473475	A	19950607

AB Hepatitis GB virus (HGBV) synthetic peptides were useful in a variety of diagnostic and analytic applications. Diagnostic kits using a viral **peptide** epitope are proposed. Methods for producing antibodies from the HGBV peptides are also proposed .

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

=> d l14 4 ibib abs

L14 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:678175 CAPLUS
DOCUMENT NUMBER: 130:95811
TITLE: Synthesis of **Peptide** Isocyanates and Isothiocyanates. [Erratum to document cited in CA125:34153]
AUTHOR(S): Nowick, James S.; **Holmes, Darren L.**; Noronha, Glenn; Smith, Eric M.; Nguyen, Tram M.; Huang, Sheng-Lin; Wang, Edward H.
CORPORATE SOURCE: Department of Chemistry, University of California, Irvine, CA, 92717-2025, USA
SOURCE: J. Org. Chem. (**1998**), 63(24), 9144
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB When L,L-phenylalanylleucine Me ester hydrochloride (L,L-1a) was converted to the corresponding isocyanate (L,L-2a) with magnetic stirring or slow (.ltoreq.300 rpm) mech. stirring, 1.3-8.8% of the epimeric isocyanate (D,L-2a) formed (Table 2). When the reaction mixt. was mech. stirred rapidly (>400 rpm), little epimerization (<0.5%) occurred. These studies show that the conditions described in the paper (rapid mech. stirring) must be used to prevent significant epimerization.

=> d l14 5 ibib abs

L14 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:720380 CAPLUS
DOCUMENT NUMBER: 127:307652
TITLE: An artificial antiparallel .beta.-sheet containing a new peptidomimetic template
AUTHOR(S): Smith, Eric M.; **Holmes, Darren L.**; Shaka, A. J.; Nowick, James S.
CORPORATE SOURCE: Department of Chemistry, University of California, Irvine, CA, 92697-2025, USA
SOURCE: J. Org. Chem. (**1997**), 62(23), 7906-7907
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB This paper reports synthetic and structural studies of artificial .beta.-sheet I, in which a 5-amino-2-methoxybenzoic hydrazide template forms a hydrogen-bonded antiparallel .beta.-sheet structure with an attached Phe-Leu dipeptide. 1H NMR chem. shift studies in CDCl3 soln. indicate that the 5-amino-2-methoxybenzoic hydrazide template is hydrogen bonded to the Phe-Leu **peptide** strand and that the hydrogen-bonding pattern is similar to that of an antiparallel .beta.-sheet. 1H NMR Tr-ROESY studies indicate proximity between the .beta.-strand mimic and the dipeptide strand in CDCl3 soln., providing compelling support for a model in which I adopts a .beta.-sheetlike conformation.

=> d l14 6 ibib abs

L14 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:696787 CAPLUS
DOCUMENT NUMBER: 127:345333
TITLE: An antigenic epitope of the A determinant of hepatitis

B surface antigen and uses thereof
INVENTOR(S): **Bridon, Dominique P.**; Qiu, Xiaoxing
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9739029	A2	19971023	WO 1997-US6732	19970418	<--
WO 9739029	A3	20010628			

W: CA, JP
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

CA 2251904	AA	19971023	CA 1997-2251904	19970418	<--
EP 906337	A2	19990407	EP 1997-921323	19970418	<--

R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL

JP 2000514643	T2	20001107	JP 1997-537434	19970418	

PRIORITY APPLN. INFO.: US 1996-635428 A 19960418
WO 1997-US6732 W 19970418

AB The subject invention relates to a **peptide** sequence corresponding to amino acid residues (117 to 128) of hepatitis B surface antigen and uses thereof. In particular, the **peptide** is an antigenic epitope and may therefore be used, for example, as a diagnostic reagent or in the prodn. of a vaccine. Furthermore, the present invention also relates to a C(K/R)TC motif present within the **peptide** as well as to other peptides contg. this motif.

=> d l14 7 ibib abs

L14 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:544318 CAPLUS
DOCUMENT NUMBER: 127:187864
TITLE: Prostate-specific antigen peptides and their use for antibody production and immunoassays
INVENTOR(S): Dowell, Barry Lee; **Bridon, Dominique P.**; Qiu, Xiaoxing; Lilja, Hans; Piironen, Timo Petteri; Vihinen, Mauno Antero; Pettersson, Immanuel Kim Sverker
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9729199	A2	19970814	WO 1997-US1911	19970206	<--
WO 9729199	A3	19980226			

W: CA, JP
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

US 6143509	A	20001107	US 1996-595945	19960206

EP 879290 A2 19981125 EP 1997-905808 19970206 <--
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL
JP 2000506520 T2 20000530 JP 1997-528662 19970206
PRIORITY APPLN. INFO.: US 1996-595945 A 19960206
WO 1997-US1911 W 19970206

AB Epitope mapping of prostate-specific antigen (PSA) allowed the prepn. of 16 **peptide** fragments which may be used, for example, in the detection of free and complexed PSA and thus in the diagnosis of prostate cancer. The peptides enable the prodn. of antisera necessary to det. the amt. of total PSA, free PSA, and PSA-.alpha.1-antichymotrypsin complex present in a sample and thus improve the ability of the clinician to distinguish, for example, between benign prostate hyperplasia and prostate cancer in a patient. **Peptide** ABT6 (CMSLLKNRFLRPGDDSC) is present in the 3-dimensional model of PSA as a protruding loop near the catalytic triad in the active site, and contains a PSA-specific epitope which is blocked by .alpha.1-antichymotrypsin (ACT) in the PSA-ACT complex; it is immunogenic and therefore has the ability to elicit antibodies. **Peptide** ABT4 (CLLGRHSLFHPEDTGQC) is an immunogenic, PSA-specific epitope which is not blocked by ACT and is present in PSA as a loop and .beta.-sheet structure distant from the catalytic triad. Antibody specificity and immunoassays using these peptides are described.

=> d l14 8 ibib abs

L14 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:528751 CAPLUS
DOCUMENT NUMBER: 127:176699
TITLE: Solid-Phase Synthesis of Artificial .beta.-Sheets
AUTHOR(S): **Holmes, Darren L.**; Smith, Eric M.; Nowick, James S.
CORPORATE SOURCE: Department of Chemistry, University of California, Irvine, CA, 92697-2025, USA
SOURCE: J. Am. Chem. Soc. (**1997**), 119(33), 7665-7669
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The solid-phase syntheses of artificial .beta.-sheets, e.g. I, which mimic

the structure and hydrogen-bonding patterns of protein .beta.-sheets is described. In these compds., mol. templates induce .beta.-sheet structures in attached **peptide** strands. The templates consist of di- and triurea derivs., which hold **peptide** and peptidomimetic strands in proximity, and .beta.-strand mimics, which hydrogen bond to the **peptide** strands. The syntheses involve constructing the "lower" **peptide** strand on Merrifield resin, attaching the di- or triamine portions of the di- or triurea templates, connecting the "upper" **peptide** and peptidomimetic strands, and cleaving the resulting artificial .beta.-sheets from the resin. The artificial .beta.-sheets were prepd. in 8-13 steps from leucine Merrifield in 33-67% overall yield.

=> d l14 9 ibib abs

L14 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:335289 CAPLUS
DOCUMENT NUMBER: 127:5344
TITLE: An Extended .beta.-Strand Mimic for a Larger Artificial .beta.-Sheet
AUTHOR(S): Nowick, James S.; Pairish, Mason; Lee, In Quen; **Holmes, Darren L.**; Ziller, Joseph W.
CORPORATE SOURCE: Department of Chemistry, University of California, Irvine, CA, 92697-2025, USA
SOURCE: J. Am. Chem. Soc. (**1997**), 119(23), 5413-5424
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB The development of .beta.-strand mimic I, which duplicates the hydrogen-bonding functionality of one edge of a tetrapeptide .beta.-strand is reported. When attached to a tripeptide by a suitable linking group, .beta.-strand mimic I forms a hydrogen-bonded antiparallel .beta.-sheet structure, artificial .beta.-sheet II. .beta.-Strand mimic I is based upon a 5-hydrazino-2-methoxybenzoic acid building block. The first half of the paper describes synthetic, IR and 1H NMR spectroscopic, x-ray crystallog., and mol. modeling studies of 5-hydrazino-2-methoxybenzoic acid derivs. and related mols. These studies establish that hydrazide derivs. of 5-hydrazino-2-methoxybenzoic acid adopt a conformation similar to that of a **peptide** .beta.-strand and are suitable for use as .beta.-strand mimics. The second half of the paper describes synthetic and 1H NMR spectroscopic studies of artificial .beta.-sheet II and of control mols. which resemble the peptidomimetic and **peptide** strands of II. These expts. indicate that II adopts a conformation and hydrogen-bonding pattern similar to that of an antiparallel .beta.-sheet and establish that .beta.-strand mimic I can induce .beta.-sheet formation in an attached **peptide** strand.

=> s l14 and blood
962301 BLOOD
L16 2 L14 AND BLOOD

=> d ibib abs

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:325963 CAPLUS
DOCUMENT NUMBER: 130:325398
TITLE: Novel conjugates of RGD-containing peptides and endogenous carriers
INVENTOR(S): **Bridon, Dominique P.**; **Ezrin, Alan M.**; **Holmes, Darren L.**; Krantz, Alexander; **Thibaudeau, Karen**; Blanchard, Dominique
PATENT ASSIGNEE(S): Conjuchem, Inc., Can.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924462	A2	19990520	WO 1998-US23702	19981106 <--
WO 9924462	A3	19990826		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9913856	A1	19990531	AU 1999-13856	19981106 <--
EP 1028971	A2	20000823	EP 1998-957648	19981106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

JP 2001522863 T2 20011120 JP 2000-520470 19981106
EP 1167383 A1 20020102 EP 2001-121557 19981106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.: US 1997-64705P P 19971107
EP 1998-956656 A3 19981106
WO 1998-US23702 W 19981106

AB Conjugates are prepd. from RGD contg. peptides, by combining said peptides or analog with a material providing a functionally reactive group capable of reacting with a **blood** component (preferably a mobile **blood** cell or endogenous protein). The conjugates may be administered to patients to provide anti-platelet or anti-adhesion properties through the inhibition of the binding of fibrinogen to the GPIIb/IIIa receptor, and may also be used as probes for receptor activity.

The administration to the patient may be made either in vivo or ex vivo and may be performed by either introducing the RGD contg. **peptide** including the reactive functional group into the patient's vascular system or prepg. such a conjugate externally and introducing that conjugate to the patient's vascular system. Thus, **peptide** Ac-RIARGDFPDDRK-NH2 was synthesized using solid-phase methods, and isolated as the tetra-trifluoroacetic acid salt or further derivatized with N-(.gamma.-maleimidobutyryloxy)succinimide or ethylene glycol-bis(succinimidyl-succinate), to give three **peptide** salts, which were then conjugated to human plasma proteins. In vivo tests, the three RGD-contg. **peptide** prepns. showed, for example, IC50 values of 5.7-27.61 .mu.M in platelet-poor plasma aggregation tests.

=> d 2 ibib abs

L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:325826 CAPLUS
DOCUMENT NUMBER: 130:349387
TITLE: Affinity markers for human serum albumin
INVENTOR(S): Krantz, Alexander; Huang, Wolin; Hanel, Arthur M.; **Holmes, Darren L.**; **Bridon, Dominique P.**
PATENT ASSIGNEE(S): Conjuchem, Inc., Can.
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924075	A2	19990520	WO 1998-US23705	19981106 <--
WO 9924075	A3	19990902		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

```
     CA 2305597         AA   19990520       CA 1998-2305597   19981106 <--
     AU 9915196         A1   19990531       AU 1999-15196     19981106 <--
     EP 1056474         A2   20001206       EP 1998-959387    19981106
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     EP 1167383         A1   20020102       EP 2001-121557    19981106
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.:                  US 1997-64705P    P  19971107
                                        US 1998-77927P    P  19980313
                                        EP 1998-956656    A3 19981106
                                        WO 1998-US23705   W  19981106
OTHER SOURCE(S):          MARPAT 130:349387
AB   Methods and compns. are provided for identifying compds. having affinity
     or complementarity to a target mol.  Compds. according to the invention
     may be described by the formula E-Ca-R-Cb-A, wherein E is a therapeutic
or
     diagnostic agent, R is a reactive group, Ca and Cb are connector groups
     between E and R and between R and A, resp., and A is a group having an
     affinity for human serum albumin, wherein affinity group A comprises a
     sequence of amino acid residues -O1-O2-X1-X2-B in which the amino acid
     residues are independently selected from the group of all twenty
naturally
     occurring amino acids.  Compds. according to the invention may be used
for
     labeling the target mol., particularly where the target mol. is naturally
     found in a complex mixt., such as a physiol. fluid, like blood.
     By affinity labeling in vivo, the lifetime of physiol. active entities
can
     be greatly enhanced by becoming bound to long-lived blood
     components.  The covalently bound entity may also serve as an antagonist
     or agonist of a particular binding protein or as an enzyme inhibitor.
One
     compd. prepd. was biotin-Gly-OPh-CO-FIYEE-NH2 (Ph = p-C6H4).


=>  log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    67.46      82.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -8.05      -8.05

STN INTERNATIONAL LOGOFF AT 15:23:56 ON 29 MAR 2002
```

WEST

Freeform Search

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term: 9924462.pn.

Display: 10 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ Hit List ◉ Hit Count ○ Side by Side ○ Image

Search | Clear | Help | Logout | Interrupt

Main Menu | Show S Numbers | Edit S Numbers | Preferences | Cases

Search History

DATE: Friday, March 29, 2002 Printable Copy Create Case